

OC.1- NOVEL CHD2 AND KIAA2022 MUTATIONS ASSOCIATED WITH EYELID MYOCLONIA WITH ABSENCES

A. Coppola¹, S. Krithika^{2,3}, M. Iacomino⁶, S. Balestrini^{2,3}, L. Hernandez-Hernandez^{2,3}, S. Meletti^{4,5}, G. Gobbi⁷, E. Ferlazzo^{8,9}, L. Giordano¹⁰, S. Casellato¹¹, V. Sofia¹², P. Striano¹³, L. Bilo¹, V. Nigro^{14,15}, A. Torella^{14,15}, F. Musacchia¹⁴, F. Zara⁶, and S.M. Sisodiya^{2,3}

¹Department of Neuroscience, Reproductive and Odontostomatological Sciences, Epilepsy Centre, Federico II University, Naples, Italy; ²Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology; ³Chalfont Centre for Epilepsy, Chalfont St Peter, UK Department of Biomedical, Metabolic, and Neural Science; ⁴University of Modena and Reggio Emilia, Modena, Italy; ⁵Neurology Unit, OCSAE Hospital, AOU Modena, Italy; ⁶Laboratory of Neurogenetics, Department of Neurosciences, Institute "G. Gaslini", Genoa, Italy; ⁷IRCCS, Institute of Neurological Sciences of Bologna, Child Neurology Unit, via Altura 3, Bologna, Italy; ⁸Department of Medical and Surgical Sciences, Magna Græcia University of Catanzaro, Viale Europa, Germaneto, Catanzaro, Italy; ⁹Regional Epilepsy Center, Great Metropolitan Hospital, Via Melacrino, Reggio Calabria, Italy; ¹⁰Child Neuropsychiatry Unit- Civile Hospital, Brescia, Italy; ¹¹Pediatric Neuropsychiatric Division Unit, AOU Sassari, Italy; ¹²Department of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania, Catania, Italy; ¹³Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, "G. Gaslini" Institute, Genova, Italy; ¹⁴Telethon Institute of Genetics and Medicine, Pozzuoli, Naples, Italy; ¹⁵Dipartimento di Biochimica, Biofisica e Patologia Generale, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy

Purpose: Eyelid myoclonia with absences (EMA) is a generalized genetic epilepsy syndrome characterised by the hallmark of rapid blinking of the eyelids and an upward deviation of the eyeballs. Understanding the genetic architecture of EMA is a challenging task as eyelid myoclonia is also seen in other epilepsy syndromes.

Method: The present study is based on a cohort of individuals with either only EMA, showing eyelid myoclonia with eye closure EEG bursts and/or photosensitivity (EMA), or with EMA associated with clinically evaluated intellectual disability or psychiatric conditions (EMA+). Whole-exome sequencing (WES) was performed on probands and their parents, when available. WES data was analysed, trios were analysed for de novo and/or unique variants and the singletons for unique variants. Sanger sequencing was used to confirm variants.

Results: We sequenced 112 individuals, including 19 trios, 40 singletons and 2 multiplex families. We identified 2 novel de novo CHD2 mutations in 2 EMA+ trios: a missense variant [c.4598 T>G] and a splice donor variant [c.3455+2 T>G]. We also identified a de novo frameshift deletion affecting KIAA2022 [c.2171del] in another EMA+ trio. All these variants were unique, with CADD score>20. Two singletons showed a previously reported mutation in the CHD2 gene: a frameshift variant [c.3734dupA] and a splice region variant [c.2577+7T>C]. The former variant was identified in an EMA+ case, and the latter in an EMA case. Overall, 10.5% of trios showed a de novo CHD2 variant and 5% of singletons harboured mutation in this gene.

Conclusion: CHD2 gene plays a key role in cerebral cortical development. Mutations in this gene have been reported for a broad spectrum of neurodevelopmental disorders, including EMA. KIAA2022 encodes a neurite extension and migration factor. Mutations in this gene have never been associated with EMA. Our study adds growing evidence implicating novel CHD2 and KIAA2022 mutations in EMA.

